Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

These can include weight loss, loss of appetite, yellowing of the skin, vomiting or nausea, and the symptoms of diabetes ...

Walmart has agreed to pay $10 million to settle a U.S. Federal Trade Commission civil lawsuit accusing the world's largest ...

Novo Nordisk is looking to partner with digital companies at every stage of the weight loss journey to help patients lose ...

Novo Nordisk launches its FDA-approved weight-loss drug Wegovy in India, rivaling Eli Lilly’s Mounjaro, as obesity and ...

Shares in Denmark's pharmaceutical giant Novo Nordisk ( NVO 0.63%) were lower by 4% as of 11 a.m. ET today. The move comes as ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake thereby reducing hunger, improving satiety and reducing cravings for food, ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

The companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through an offering on the telehealth company's platform.

In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer.

Driven by a desire to help ex-servicemembers with post-traumatic stress disorder and other mental illnesses, GOP lawmakers ...